medisourceasia.com

Industry News


Home

About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Positive contributors to operational results were US sales of Tylenol and Motrin analgesics; upper respiratory over-the-counter products; international sales of baby care products; sales of Neutrogena and Aveeno skin care products; and international sales of Listerine oral care products. Primary contributors to operational sales growth were Remicade (infliximab) and Simponi (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; Stelara (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis; Invega Sustenna/ Xeplion (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; Prezista (darunavir), a treatment for HIV; Doxil (doxorubicin HCl liposome injection)/ Caelyx (pegylated liposomal doxorubicin hydrochloride), a medication to treat recurrent ovarian and other cancers; Velcade (bortezomib), a treatment for multiple myeloma; and sales of new products. The strong sales results of new products included Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; Xarelto (rivaroxaban), an oral anticoagulant; the combined sales of Complera/Eviplera (emtricitabine /rilpivirine/tenofovir disoproxil fumarate) and Edurant (rilpivirine) for the treatment of HIV and Invokana (canagliflozin) for the treatment of adults with type 2 diabetes. Sales results were negatively impacted by loss of exclusivity for Aciphex/ Pariet (rabeprazole), a proton pump inhibitor for gastrointestinal disorders and Concerta (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder. Primary contributors to operational growth were sales from the acquisition of Synthes, Inc. and joint reconstruction products in the orthopaedics business; Biosense Webster’s electrophysiology products in the cardiovascular care business; the vision care business; as well as biosurgicals and international sales of energy products in the specialty surgery business.

 

http://www.pharmabiz.com/PrintArticle.aspx?aid=79924&sid=2


Lilly India & Boehringer Ingelheim India Launch 'Next Generation' Re-Usable Insulin Pen – HumaPen SAVVIO

 

Eli Lilly and Company India (Lilly), a leading innovation-driven corporation, and Boehringer Ingelheim India, the world’s 20 leading pharmaceutical companies, recently announced the launch of HumaPen SAVVIO, an innovative insulin delivery pen that meets the diabetics’ individual need. This latest innovation is engineered to resemble as a small personal accessory rather than a medical device.

 

HumaPen SAVVIO, an invention by Lilly, offers an extended shelf life of up to six years after first use. It was designed following feedback from people with diabetes who shared their aspiration to manage diabetes discreetly.

 

HumaPen SAVVIO, an original research product of Lilly will be co-promoted by the Lilly-Boehringer Ingelheim alliance in India.

 

Announcing the launch, Edgard Olaizola, managing director, Eli Lilly and Company India said, “The launch of HumaPen SAVVIO marks an important milestone for Lilly, reflecting our ongoing commitment to develop ‘people-led’ innovative solutions for diabetes. At Lilly, we recognize that people are unique and that their insulin delivery devices should reflect their lifestyle and personality. That’s why we developed HumaPen SAVVIO to be lightweight, portable and available in a choice of colours. It will help to bring a greater sense of normalcy to using insulin. We will continue to introduce innovative products to address the unmet needs of patients amidst the growing Indian diabetes epidemic.”

 

Commenting on the launch, Sharad Tyagi, managing director, Boehringer Ingelheim India said, “After the successful launch of Trajenta by the Lilly-Boehringer Ingelheim Alliance, this is another revolutionary product for the huge diabetes market in India. HumaPen Savvio is in line with alliance’s ongoing commitment to provide innovative solutions for diabetes treatment. We are constantly working towards pioneering interventions by leveraging scientific know-how and commercial capabilities of both companies and expanding our product portfolio for diabetes in India.”

 

The new HumaPen SAVVIO is short in size, lightweight, dependable, durable, easy to use insulin pen that will improve the everyday lives of people with diabetes. To boost the personal confidence of diabetics, the device is designed similar to a fashionable, compact pen with durable design and will be available in a range of colours - red, graphite, green and silver. HumaPen SAVVIO also makes dosing easy and insulin delivery discreet, which helps insulin users feel more at ease when using their medication.

 

HumaPen SAVVIO is supported by Lilly’s Diabetes Educators Service. Spread across the country, Diabetes Educators provide education/counselling on diabetes, nutrition, self-management, lifestyle management, hypoglycaemia and appropriate use of injectable devices under the guidance of treating physicians.

 

HumaPen SAVVIO will be available in India across six metros viz. Delhi, Mumbai, Kolkata, Chennai, Hyderabad and Bengaluru for use with 3 mL insulin cartridges Humalog, Humalog Mix25 and Humalog Mix50 on doctor’s prescription.

 

http://www.pharmabiz.com/ArticleDetails.aspx?aid=79919&sid=2

Other News

Medical Device Innovator Spreads Winds In Country
Medical Device Plastic Material Innovations To Watch

Arkray Group To Acquire IVD Business Of Span Diagnostics For Rs.100 Crore

US-Based Merit Medical Systems Opens Office In Bengaluru

Johnson & Johnson Adjusted Net Earnings Up By 37% In Q4
Lilly India & Boehringer Ingelheim India Launch 'Next Generation' Re-Usable Insulin Pen – HumaPen SAVVIO
Evonik Launches Care Product Lines Designed Specifically For Medical Market
New Silicone Film From Wacker For Wound Dressing
Plastic Device Aids Knee Replacement
Mediprene TPE Used For Radial Compression Device
Innovations In Plastic Drive Past, Present & Future Medical Care
Creating Medical Plastics That Heal Themselves
MedTechs Tackle Replacing 'Workhorse' Plasticizer
Plastic Injection Protects Mouse Hearts After Attack
New Packaging Plastic That Protects As Good As Aluminium Foil
3 Major Trends In Barcode Labeling For Medical Devices
ASEAN Countries Could Be The Next Emerging MedTech Markets
Invent Bio-Med’s Nova Vida Chrome Gets CE Certification

Archives

Advertisement

 

 


Back | Back To Top | Previous | Next